Bcl-6

Bcl-6

A protein that marks germinal center-cell differentiation and regulates lymphocyte differentiation and immune response. Bcl-6 gene rearrangements and Bcl-6 protein expression are frequent in nodular lymphocyte-predominant Hodgkin lymphoma and suggest a germinal center-derived B-cell origin for Barrett esophagitis.
See also: Barrett epithelium, Barrett syndrome.

Bcl-6

A 79-kDa POZ/zinc finger transcriptional repressor and proto-oncogene that maps to chromosome 3q27, which plays a role in B cell activation and proliferation within the germinal centre, and thus is a marker for germinal centre cells and germinal centre lymphomas, especially those lacking gene rearrangements.

Normal expression
Bcl-6 represses lymphocyte activation genes, including blimp-1, which plays a role in plasma cell differentiation. Bcl-6 may thus trigger malignant transformation by inhibiting terminal plasma cell differentiation.

Abnormal expression
Bcl-6 overexpression delays progression through the S phase of the cell cycle/apoptosis, and is present in one third of diffuse large B cell lymphomas
References in periodicals archive ?
Then, using BCL-6 as a biomarker, the team used several methods to inhibit B-cell antigen receptor signaling, including treating cells with targeted compounds used in human lymphoma.
However, the characteristic cytogenetic abnormalities involve chromosomal rearrangements of c-MYC, BCL-2, and BCL-6 genes.
Coexpression of CD10 and BCL-6 has been used as a marker of presumptive germinal center origin and has also been suggested to have prognostic implications, but this remains controversial.
During the study, researchers identified a molecule called heat shock protein 90 (Hsp90) that play a vital role in functioning of a protein called BCL-6, known to drive the activity of lymphoma tumour cells.
While there is tumor individuality, the neoplastic cells usually show a B cell phenotype (CD19, CD20, CD22, CD79a) with coexpression of CD10 and CD43; they also express bcl-2 and bcl-6 and demonstrate light-chain (kappa or lambda) restriction.
5 /PRNewswire/ -- Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).
today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.
bcl-6 gene rearrangement appears to play a role in the pathogenesis of FL, and like with diffuse large B-cell lymphoma, it may correlate with a favorable prognosis.
However, BCL-6 was expressed in all 3 cases studied, and bcl-6 gene rearrangement was found in the one case evaluated by Southern blot analysis.
The antibodies used were specific for CD45RB (leukocyte common antigen; 1:300, Dako Corporation, Carpinteria, Calif), CD3 (1:150, Dako), CD20 (L26; 1:700, Dako), CD79a (1:50, Dako), [Kappa] immunoglobulin light chain (1:10000, Dako), [Lambda] immunoglobulin light chain (1:10000, Dako), Bcl-6 (1: 10, Dako), epithelial membrane antigen (1:25, Dako), CD10 (1:70, Vector, Burlingame, Calif), CD30 (1:20, Signet, Dedham, Mass), Bcl-2 (1:200, BioGenex, San Ramon, Calif), Ki-67 (1:20, Beckmann Coulter, Miami, Fla), keratin (AE1/AE3; 1:500, Boehringer Mannheim, Indianapolis, Ind), [Alpha]-fetoprotein (1:25, Zymed Lab, San Francisco, Calif), and placental alkaline phosphatase (1:20, Lab Vision Corp, Freemont, Calif).